Capecitabine Monotherapy as Palliative Treatment for Patients with Recurrent/Metastatic Nasopharyngeal Cancer

Table 3

Regression analysis of variables associated with an objective response rate of capecitabine in R/M NPC.

Variables	Univariate analysis
	OR	95% CI	-value
ECOG-PS 0/1 vs. 2	1.26	0.39–4.06	0.69
De novo metastases vs. relapsed	0.67	0.22–2.04	0.48
Sites of metastasis
Lung vs. others	1.07	0.35–3.23	0.89
Liver vs. others	0.80	0.24–2.53	0.69
Bone vs. others	0.67	0.22–2.04	0.49
Brain vs. others	0.29	0.02–3.02	0.30
1^st/2^nd line vs. subsequent lines	1.07	0.35–3.24	0.90
Starting dose	0.41	0.13–1.28	0.12
Lower vs. standard dose ^a
Highest achieve dose
Standard dose vs. lower dose	1.32	0.34-5.06	0.67
History of smoking vs. none	0.13	0.02–0.8	0.02
Development of HFS vs. none	5.5	1.29–23.3	0.02

^aLower starting dose are 850 mg/m² or 1000 mg/m² and standard dose is 1250 mg/m^2. Abbreviations: CI: confidence interval; ECOG-PS: Eastern Cooperative Oncology Group Performance Status; HFS: hand-foot syndrome; NPC: nasopharyngeal carcinoma; OR: odds ratio; R/M: recurrent/metastatic.